TheranosticTrials.org

Clinical Trial · NCT04685811

Evaluation of PSMA Antagonist Produced by Two Different Methods

Overview

Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers. The goal of the study is to evaluate repeatability and equivalence across the different 68Ga-PSMA production methods. This research study is being conducted to assess whether the PET/CT imaging results, as generated from the two different 68Ga production methods, are equivalent.

Sponsor

Weill Medical College of Cornell University

Phase

Phase 1/2

Contacts

Joseph R Osborne, M.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04685811

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

Eligibility

Inclusion

  • Histologically confirmed diagnosis of metastatic prostate cancer
  • Subjects must meet all of the following criteria to be enrolled in this study:
  • Staging imaging exam confirming metastatic disease, e.g. total body MRI, or CT chest/abdomen/pelvis, 99mTc bone scan, NaF PET

Exclusion

Exclusion criteria not yet provided.